On the physiological relevance of muscarinic acetylcholine receptors in Alzheimer's disease

Current Medicinal Chemistry

Volumn 12, Issue 24, 2005, Pages 2915-2921

  Koch, Horst J ^a   Haas, S ^a   Jurgens T ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Agonist; Antagonist; Dementia; Muscarinic receptors

Indexed keywords

4 DIPHENYLACETOXY 1 METHYLPIPERIDINE; [4 [(3 CHLOROPHENYL)CARBAMOYLOXY] 2 BUTYNYL]TRIMETHYLAMMONIUM; ACETYLCHOLINE; ALVAMELINE; BETHANECHOL; CEVIMELINE; CHOLINESTERASE INHIBITOR; DIHYDROERGOTOXINE; G PROTEIN COUPLED RECEPTOR; GALANTAMINE; HIMBACINE; MEMANTINE; METHOCTRAMINE; MILAMELINE; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NEBRACETAM; NERVE PROTEIN; NICERGOLINE; PILOCARPINE; PIRACETAM; SABCOMELINE; TALSACLIDINE; TELENZEPINE; TRIPITRAMINE; UNINDEXED DRUG; XANOMELINE;

ACETYLCHOLINE RELEASE; ALZHEIMER DISEASE; ANTICHOLINERGIC EFFECT; BRADYCARDIA; BRONCHOSPASM; CHOLINERGIC NERVE CELL; CLINICAL TRIAL; DEMENTIA; DIARRHEA; DRUG BINDING SITE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; FOREBRAIN; HUMAN; HYPOTENSION; NAUSEA; PARKINSONISM; PATHOPHYSIOLOGY; PROTEIN DEPLETION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKILL; STRUCTURE ANALYSIS; SWEATING; VOMITING;

ALZHEIMER DISEASE; HUMANS; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; MUSCARINIC AGONISTS; MUSCARINIC ANTAGONISTS; RECEPTORS, MUSCARINIC; SIGNAL TRANSDUCTION;

EID: 27744583479     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986705774454742     Document Type: Review

References (92)

1. Selkoe, D.J. Physiol. Rev., 2001, 81, 741.
2. Gasparini, I.; Racchi, M.; Binetti, G.; Trabucchi, M.; Solerte, S.B.; Alkon, D.; Etcheberrigaray, R.; Gibson G. FASEB J. 1998, 12, 17.
3. Kihara, T.; Shimohama S. Acta Neurobiol. Exp., 2004, 64, 5.
4. Ibach, B.; Haen, E. Current Pharmaceutical Design, 2004, 3, 231.
5. Camps, P.; Munoz-Torrero, D., Mini Rev. Med. Chem., 2002; 2: 11.
6. Koch, H.J.; Szecsey, A.; Haen E. Current Pharmaceutical Design, 2004, 3, 253.
7. Jope, R.S. Alzheimer's Disease Review, 1996, 1, 2.
8. Lee, R.K.K.; Wurtman, R.J.; Cox, A.J.; Nitsch, R.M. Proc. Natl. Acad. Sci USA, 1995, 92, 8083.
9. Nitsch, R.M; Growdon, J.H. Biochem. Pharm., 1994, 47, 1275.
10. Checler, F. J. Neurochem., 1995, 65, 1431.
11. Mattson, M.P.; Barger, S.W.; Cheng, B.; Lieberburg, I.; Smith-Swintoski, V.L.; Rydel, R.E. Trends in Neurosci., 1993, 16, 409.
12. Loo, D.T.; Copani, A.; Pike, C.J.; Whittemore, E.R.; Walencewicz, A.J.; Cotman, C.W. Proc. Natl. Acad. Sci., 1993, 90, 7951.
13. Doerfler, P.; Shearman, M.S; Perlmutter, R.M. Proc. Natl. Acad. Sci. USA, 2001, 98, 9312.
14. Brown, M. Drug Discov. Today, 2003, 8, 474.
15. Mandelkow, E. Nature, 1999, 402, 588.
16. Huang, X.; Cuajungco, M.P.; Atwood, C.S.; Hartshorn, M.A.; Tyndall, J.D.; Hanson, G.R.; Stokes, K.C.; Leopold, M.; Multhaup, G.; Goldstein, L.E., Scarpa, R.C.; Saunders, A.J.; Lim, J.; Moir, R.D.; Glabe, C.; Bowden, E.F.; Masters, C.L.; Fairlie, D.P.; Tanzi, R.E.; Bush, A.I. J. Biol. Chem., 1999, 274, 37111.
17. Sherwin, BB. Trends Pharmacol. Sci., 2002, 23, 527.
18. Kordower, J.H.; Isacson, O.; Emerich, D.F. Exp. Neurol. 1999, 159, 4.
19. Suh, Y.H.; Checler, F. Pharmacol. Rev., 2002, 54, 469.
20. Müller, W.E.; Juretzek, W. In Neuropsychopharmaka - Ein Therapie-Handbuch; Riederer, P.; Laux, G.; Pöldinger, W.; Springer, Wien New York, 1999, Vol 5, pp. 623-658.
21. Helmuth, L. Science, 2002, 297, 1260.
22. Breitner, J.C. Lancet Neurol., 2003, 2, 527.
23. Koch, H.J. Polish J. Pharmacol., 1998, 50, 39.
24. Herrschaft, H. In Neuropsychopharmaka - Ein Therapie-Handbuch; Riederer, P.; Laux, G.; Pöldinger, W.; Springer, Wien New York, 1999, Vol. 5, pp. 530-541.
25. Scarpini, E.; Scheltens, P.F.; Feldman, H. Lancet Neurol., 2003, 2, 539.
26. Perry, E.; Martin-Ruiz, C.; Lee, M.; Griffith, M.; Johnson, M.; Piggot, M.; Haroutunian, V.; Buxbaum, J.D.; Nasland, J.; Davis, K.; Gotti, C.; Clementi, F.; Tzartos, S.; Cohen, O.; Soreq, H.; Jaros, E.; Perry, R.; Ballard, C.; McKeith I.; Court, J. Eur. J. Pharmacol., 2000, 393, 215.
27. Maelicke, A.; Albuquerque, E.X. Eur. J. Pharmacol., 2000, 393, 165.
28. Rösler, M. In: Neuropsychopharmaka - Ein Therapie-Handbuch; Riederer, P.; Laux, G.; Pöldinger, W.; Springer, Wien New York, 1999, Vol. 5, pp. 714-720.
29. Birdsall, N. J. In: The IUPHAR Compendium of Receptor Characterization and Classification, IUPHAR Media London, 2000, pp. 54-63.
30. Hosey, M.M.; DebBurman, S.K.; Pals-Rylaarsdam, R.; Richardson, R.M.; Benovic, J.H. Prog. Brain Res., 1996, 190, 169.
31. Porzig, H.; Häusler, G. In: Pharmakologie und Toxikologie; Estler C.J., Ed., Schattauer, Stuttgart, 1999, pp. 46-120.
32. Kenneth, L.D. In: Psychopharmacology: the Fifth Generation of Progress, Kenneth, L.D.; Charney, D.; Nemeroff, J.C.; Eds, American College of Neuropsychopharmacology, Lippincott, Williams & Wilkins, 2002, Chap.87.
33. Leiros, C.P.; Sterin-Borda, L.; Hubscher, O.; Arana, R.; Borda, E.S. Clin. Immunol., 1999, 90, 190.
34. Dawson, T.M.; Dawson, V.L. Ann. Rev. Med., 1996, 47, 219.
35. Jaffrey, S.R.; Snyder, S. Science, 1996, 274, 774.
36. Van den Oord, A. Brit. J. Dermatol., 1999, 1365.
37. Haley, J.C.; Delmas, P.; Offermanns, S.; Abogadie, F.C.; Simon, M.J.; Buckley, N.J.; Brown, D.A. J. Neurosci., 2000, 20, 3973.
38. Shapiro, M.S.; Gomeza, J.; Hamilton, S.E.; Hille, B.; Loose, M.D.; Nathanson, N.M.; Roche, J. P.; Weiss, J. Life Sciences, 2001, 68, 2481.
39. Broadley, K.J.; Kelly, D.R. Chemistry Reprint Server: medichem/0009001.
40. Levy, A. I. Proc. Natl. Acad. Sci., 1996, 93, 13541.
41. Valentino, R.J.; Dingledine, R. J. Neurosci., 1981, 1, 784.
42. Raiteri, Marchi, M.; Paudice, P, Ann. NY Acad. Sci., 604, 1990, 113.
43. Kahle, J. S.; Cotman, C.W. Brain Res., 1989, 482, 159.
44. Felder, C.C. FASEB J., 1995, 9, 619.
45. Bock, K.W.; Klotz, U. In Pharmakologie und Toxikologie; Estler C.J., Ed., Schattauer, Stuttgart, 1999, pp. 1-45.
46. Teber, I.; Köhling R.; Speckmann, E.-J.; Barnekow, A.; Kremerskothen, J. Mol. Brain. Res., 2004, 121, 131.
47. Anderson, K.-E. European Urology, 1998, 34, 6.
48. Bonner, T.I.; Buckley, N.J.; Young, A.C.; Brann, M.R. Science, 1987, 237, 527.
49. Reiner, P.B.; Fibiger, H. C. In Functional Heterogeneity of the Cerebral Cholinergic System - The Fourth Generation of Progress, Bloom, F.E.; Kupfer, D.J., Eds., American College of Neuropsychopharmacology. Lippincott Williams and Wilkins, is Baltimore, 2000.
50. Birdsall, N.J.; Farries, T.; Charagozloo, P.; Kobayashi, S.; Kuonen, D.; Lazareno, S.; Popham, A.; Sugimoto, M. Life Sci., 1997, 60, 1047.
51. Jope RS. Alzheimer's Dis. Rev., 1996, 1, 2.
52. Gu, Z.; Zhong, P.; Zhen, Y. J. Biol. Chemistty, 2003, 278, 17546.
53. Soderling, T.R. Curr. Opin. Neurobiol., 2000, 10, 375.
54. Wang, H.-Y.; Friedman, E. Neurosci. Lett., 1994, 173, 37.
55. Litersky, J.M.; Seubert, P.; Lee, V.M.; Jakes, R.; Goedert, M.; Johnson, G.V.W. Soc. Neurosci. Abstr., 1995, 21, 742.
56. Pearce, B.D.; Potter, L.D. Alz. Dis. Assoc. Disorders, 1991, 5, 163.
57. Greenwood, A.F.; Powers, R.E.; Jope, R.S. Neuroscience, 1995, 69, 125.
58. Flynn, D.D.; Weinstein, D.A.; Mash, D.C. Ann. Neurol., 1991, 29, 256.
59. Stokes, C.E.; Hawthorne, J. E. J. Neurochem., 1987, 48, 1018.
60. Bothmer, J.; Markerink, M.; Jolles, J. Dementia, 1994, 5, 6.
61. Ohm, T.G. Hippocampus, 1993, 3, 131.
62. Garlind, A.; Cowburn, R.F.; Forsell, C.; Ravid, R.; Winblad, B.; Fowler, C. J. Brain Res., 1995, 681, 160.
63. Jin, L.-W.; Saitoh, T. Drugs Aging, 1995, 6, 136.
64. Fisher, A.; Brandeis, R.; Bar-Ner, R.H.; Kliger-Spatz, M.; Natan, N.; Sonego, H.; Marcovitch, I.; Pittel, Z. J. Mol. Neurosci., 2002, 19, 145.
65. Carey, G.J.; Billard, W.; Binch, H.; Cohen-Williams, M.; Crosby, G.; Grzelak, M.; Guzik, H.; Kozlowski, J.A.; Lowe, D.B.; Pond, A.J.; Tedesco, R.P.; Watkins, R.P.; Coffin, V.L. Eur. J. Pharmacol., 2001, 16, 189.
66. Tzvara, E.T.; Bymaster, F.P.; Felder, C.C.; Wade, M.; Gomeza, J.; Wess, J., McKinzie, D.L.; Nomikos, G.G. Mol. Psychiatry, 2003, 8, 673.
67. Mulugeta, E.; Karlsson, E.; Islam, A.; Kalaria, R.; Mangat, H.; Winblad, B.; Adem, A. Brain Res., 2003, 960, 259.
68. Mirza, N.R.; Peters, D.; Sparks, R.G. CNS Drug Rev., 2003, 9, 159.
69. Bymaster, F.P.; Felder, C.; Ahmed, S.; McKinzie, D. Curr. Drug Targets CNS Neurol. Disord., 2002, 1, 163.
70. Lai, M.K.; Lai, O.F.; Keene, J.; Esiri, M.M.; Francis, P.T.; Hope, T.; Chen, C.P. Neurology, 2001, 6, 57, 805.
71. Larzareno, S.; Popham, A.; Birdsall, N.J. J. Mol. Neurosci., 2002, 19, 123.
72. Elvander, E.; Schott, P.A.; Sandin, J.; Bjelke, B.; Kehr, J.; Yoshitake, T.; Ogren, S.O. Neuroscience, 2004, 126, 531.
73. Bai, J.P.F.; Stewart, B.H.; Amidon, G.L. In Pharmacokinetics of Drugs - Gastrointestinal transport of peptide and protein drugs and prodrugs. Welling, P.G.; Balant, L.P.; Eds.; Springer Verlag, Berlin, 1994, pp. 189-203.
74. Hussain, M.A.; Mollica, J.A. J. Pharm. Sci., 1991, 80, 750.
75. Benet, L.Z.; Mitchell, J. R., Sheiner L.B. In The Pharmacological Basis of Therapeutics, Goodman, A.G.; Rall, T.W.; Nies, A.S.; Taylor, P., Eds., Vol. I, McGraw Hill, NY, 1992, pp. 3-32.
76. Growdon, J. Life Sci., 1997, 60, 993.
77. Davis, D.; Hollander, E.; Davidson, M.; Davis, B.; Mohs, R.; Horvath, T. Am. J. Psychiatry, 1987, 144, 468.
78. Hollander, E.; Davidson, M.; Mohs, R.; Horvath, T.; Davis, B.; Zemishlany, Z.; Davis, K. Biol. Psychiatry, 1987, 22, 1067.
79. Tarriot, P.; Cohen, R.; Welkowitz, J.; Sunderland, T.; Newhouse, P.; Murphy, D.; Weingartner, H. Arch. Gen. Psychiatry, 1988, 45, 901.
80. Rösler, M.; Heidrich, A. In Neuropsychopharmaka - Ein Therapie-Handbuch; Riederer, P.; Laux, G.; Pöldinger, W.; Springer, Wien New York, 1999, Vol. 5, pp. 753-770.
81. Fisher, A.; Pittel, Z.; Haring, R.; Bar-Ner, N.; Kliger-Spatz, M.; Natan, N.; Egozi, I.; Sonego, H.; Marcovitch, I., Brandeis, R. Mol. Neurosci., 2003, 20, 349.
82. Harrison, P.J.; Barton, A.J.L.; Najlerahim, A.; McDonald, B.; Pearson R.C.A. Mol. Brain Res., 1991, 9, 15.
83. Graul A, Castaner, J. Drugs Fut., 1997, 21, 1124.
84. Bodick, N.C., Offen, W.W.; Shannon, HE. Alz. Dis. Assoc. Disord., 1997, 11 (suppl 4), S16.
85. Ensinger, H.A.; Bechtel, W.D.; Birke, F.W. Drug Dev. Res., 1997, 40, 144.
86. Hatcher, J.P.; Loudon, J.M., Hagan, J.J., Clark, M.S.G. Psychopharmacolgoy, 1998, 138, 275.
87. Mucke, H.; Castaner J. Drugs Fut., 1998, 23, 843.
88. Fisher, A.; Heldman, F.; Gurwitz, D. Ann. NY Acad. Sci., 1996, 777, 189.
89. Fox, R.I. Expert Opin. Investig. Drugs, 2003, 12, 247.
90. Kohno, Y.; Shibata, S. CNS Drug Rev., 1996, 2, 1.
91. Greenlee, W.; Clader, J.; Asberom, T.; McCombie, S.; Ford, J.; Guzik, H.; Kozslowski, J.; Li, S.; Liu, C.; Lowe, D.; Vice, S.; Zhao, H.; Zhou, G.; Billard, W.; Binch, H.; Crosby, R.; Duffy, R.; Lachowicz, J.; Coffin, V.; Watkins, R.; Ruperto, V.; Strader, C.; Taylor, L.; Cox, K. Farmaco, 2001, 65, 247.
92. Alberts, B.; Bay, D.; Lewis J. Molecular Biology of the Cell. 3rd Edition. Garland Science, NY, 1994.